• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Roszdravnadzor extend the powers of inspection

02.09.2021/in Publications /by Marketing

The Russian Ministry of Health has developed amendments to the Regulation on the Federal Service for Surveillance in Healthcare. The draft was prepared to implement the Agreement on Common Principles and Rules of Circulation of Medical Devices and Medicines in the Eurasian Economic Union (EAEU). The draft provides for the formation of common markets for medical devices and medicines within the Eurasian Economic Union and the adoption of measures necessary for the harmonization and unification of the legislation of member states of the Union in the sphere of circulation of medical devices and medicines. The draft document is available at: https://regulation.gov.ru/projects#npa=106260.

 The list of proposed changes:

 – Inspection of testing laboratories and audits of preclinical (non-clinical) studies of medicines for compliance with the Good Laboratory Practice (GLP) Rules of the EAEU.

 Thanks to this change the authorized bodies will check the procedures and practices of the laboratory to assess compliance with the principles of GLP.

 There also appeared a similar point for inspection of clinical trials according to the Good Clinical Practice (GCP) rules.

 – Implementation of inspection of organizations conducting clinical trials of medicines for compliance with GCP.

 Within the framework of this inspection, the authorized bodies inspect documents, infrastructure, records, quality assurance agreements, and any other sources which are considered by the authorized body as relevant to the study and which may be located in the research center, facilities of the sponsor and/or contract research organization or in other organizations which, in the opinion of the authorized body, require inspection.

 The next point of amendments concerns compliance with the implementation of the Good Distribution Practice (GDP) Rules.

 – Verification of compliance of subjects of circulation of medicines for medical use with proper conditions for storage, transportation, and distribution of medicines according to GDP.

 In addition, as part of these changes were added paragraphs regulating the implementation of pharmacovigilance by Good Pharmacovigilance Practice (GVP).

 – Conducting pharmacovigilance inspections of licensees or other organizations engaged by licensees to perform pharmacovigilance obligations.

 – Monitoring the safety, quality, and effectiveness of medical devices by the Rules for monitoring the safety, quality, and effectiveness of medical devices, approved by the decision of the Eurasian Economic Collegium on December 22, 2015, № 174;”.

 Thus, the approval of these changes, on the one hand, will harmonize and unify the legislation of EAEU member states, and, on the other hand, ensure compliance with GLP, GCP, GDP, and GVP rules in our country.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

4 + 4 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Readability User Testing of Package Information Leaflets (PIL) in EAEU Contact person for pharmacovigilance
Scroll to top